
Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal. The conversation touches upon regulatory strategy and evolving policy shifts, trial design and execution – and the importance of patient centricity – as well as AI in drug development and medical leadership in drug development today. You can listen to episode 266 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

CAMP4 on a new class of ASO in gene under expression

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

Purespring on nephrology & gene therapy in kidney disease
Free AI-powered recaps of pharmaphorum Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.